Bevacizumab Treatment For Type 1 ROP (NCT04634578)
Bevacizumab Treatment For Type 1 Retinopathy of Prematurity
🩺 Plain-English Summary (8th-Grade Level)
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.
Who can join: Review the eligibility criteria below.
Location: Arkansas Childrens Hospital/ University of Arkansas Medical Sciences — Little Rock, Arkansas
Age range: Not specified to 6 Months
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- Arkansas Childrens Hospital/ University of Arkansas Medical Sciences — Little Rock, Arkansas
- Univ of California, Irvine- Gavin Herbert Eye Institute — Irvine, California
- Jules Stein Eye Institute at the University of California, Los Angeles — Los Angeles, California
- University of California, Davis — Sacramento, California
- University of California San Francisco Department of Ophthalmology — San Francisco, California
- The Emory Eye Center — Atlanta, Georgia
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
- U of Illinois at Chicago Eye and Ear Infirmary — Chicago, Illinois
- University of Chicago — Hyde Park, Illinois
- Indiana University School of Medicine — Indianapolis, Indiana
- Riley Hospital for Children — Indianapolis, Indiana
- UK Ophthalmology and Visual Sciences, The Eye Clinic — Lexington, Kentucky
- Greater Baltimore Medical Center — Baltimore, Maryland
- Boston Children's Hospital — Boston, Massachusetts
- New York Presbyterian David H Koch Center — New York, New York
- Duke University Eye Center — Durham, North Carolina
- Cincinnati Children's Hospital — Cincinnati, Ohio
- Pediatric Ophthalmology Associates, Inc. — Columbus, Ohio
- Casey Eye Institute — Portland, Oregon
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- UPMC Children's Eye Center of Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania
- Storm Eye Institute — Mt. Pleasant, South Carolina
- Texas Children's Hospital - Dept. Of Ophthalmology — Houston, Texas
- University of Utah Moran Eye Center — Salt Lake City, Utah
- Virginia Pediatric Eye Center — Norfolk, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Retinopathy of Prematurity
- Validation of i-ROP DL to Detect More Than Mild ROP — Portland, Oregon
- Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next) — La Jolla, California
- Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2) — Durham, North Carolina
- Clinical and Genetic Analysis of ROP — Palo Alto, California
- Imaging Retinal Vasculature in Infant Eyes — Durham, North Carolina
Explore by condition: All Retinopathy of Prematurity clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.